Aileron Therapeutics Files 8-K
Ticker: RNTX · Form: 8-K · Filed: Apr 15, 2024 · CIK: 1420565
| Field | Detail |
|---|---|
| Company | Aileron Therapeutics, Inc. (RNTX) |
| Form Type | 8-K |
| Filed Date | Apr 15, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, 8-k
TL;DR
Aileron Therapeutics filed an 8-K on 4/15/24 for financial reporting, no new info.
AI Summary
Aileron Therapeutics, Inc. filed an 8-K on April 15, 2024, reporting on its results of operations and financial condition, and including financial statements and exhibits. The filing does not contain specific financial figures or operational updates beyond the reporting of these items.
Why It Matters
This 8-K filing indicates that Aileron Therapeutics is providing updates on its financial condition and operations, which is standard for public companies but lacks specific details in this instance.
Risk Assessment
Risk Level: low — The filing is a routine 8-K for financial reporting and does not disclose any new material events or risks.
Key Players & Entities
- Aileron Therapeutics, Inc. (company) — Registrant
- April 15, 2024 (date) — Date of report
- Delaware (jurisdiction) — State of incorporation
- 001-38130 (identifier) — SEC File Number
- 13-4196017 (identifier) — IRS Employer Identification No.
- 12407 N. Mopac Expy. Suite 250 #390 Austin, Texas 78758 (address) — Principal Executive Offices
- (737) 802-1989 (phone_number) — Registrant's telephone number
FAQ
What is the primary purpose of this 8-K filing by Aileron Therapeutics, Inc.?
The primary purpose of this 8-K filing is to report on the Results of Operations and Financial Condition, and to include Financial Statements and Exhibits.
On what date was this 8-K report filed?
This 8-K report was filed on April 15, 2024.
In which U.S. state is Aileron Therapeutics, Inc. incorporated?
Aileron Therapeutics, Inc. is incorporated in Delaware.
What is the principal executive office address for Aileron Therapeutics, Inc.?
The principal executive office address is 12407 N. Mopac Expy. Suite 250 #390, Austin, Texas 78758.
Does this filing provide specific financial results or operational updates?
No, this filing is a notification of reporting on results of operations and financial condition, and includes financial statements and exhibits, but does not detail specific figures or updates within the provided text.
Filing Stats: 446 words · 2 min read · ~1 pages · Grade level 10.3 · Accepted 2024-04-15 17:22:03
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value per share ALRN The Nasdaq
Filing Documents
- d817402d8k.htm (8-K) — 25KB
- d817402dex991.htm (EX-99.1) — 46KB
- g817402g0415065037236.jpg (GRAPHIC) — 3KB
- 0001193125-24-096389.txt ( ) — 207KB
- alrn-20240415.xsd (EX-101.SCH) — 3KB
- alrn-20240415_lab.xml (EX-101.LAB) — 18KB
- alrn-20240415_pre.xml (EX-101.PRE) — 11KB
- d817402d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits (d) Exhibits. Exhibit Number Document 99.1 Press Release, dated April 15, 2024 104 Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AILERON THERAPEUTICS, INC. Date: April 15, 2024 By: /s/ Brian Windsor, Ph.D. Brian Windsor, Ph.D. President and Chief Executive Officer